Parabilis Medicines, Inc. (PBLS)
NASDAQ: PBLS · Real-Time Price · USD
31.96
+0.14 (0.44%)
At close: Jul 28, 2026, 4:00 PM EDT
31.75
-0.21 (-0.65%)
After-hours: Jul 28, 2026, 7:34 PM EDT
Parabilis Medicines Market Cap
Parabilis Medicines has a market cap or net worth of $4.07 billion as of July 28, 2026.
Market Cap
4.07B
Enterprise Value
3.79B
1-Year Change
n/a
Ranking
Category
Stock Price
$31.96
ChartMarket Cap Chart
Since the IPO on June 10, 2026, Parabilis Medicines's market cap has increased from $2.38B to $4.07B, an increase of 71.35%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 28, 2026 | 4.07B | 0.44% |
| Jul 27, 2026 | 4.05B | 1.73% |
| Jul 24, 2026 | 3.98B | -4.66% |
| Jul 23, 2026 | 4.18B | 6.49% |
| Jul 22, 2026 | 3.92B | 2.56% |
| Jul 21, 2026 | 3.83B | 10.00% |
| Jul 20, 2026 | 3.48B | -7.58% |
| Jul 17, 2026 | 3.76B | 1.69% |
| Jul 16, 2026 | 3.70B | -2.84% |
| Jul 15, 2026 | 3.81B | -3.98% |
| Jul 14, 2026 | 3.97B | 5.13% |
| Jul 13, 2026 | 3.77B | -3.07% |
| Jul 10, 2026 | 3.89B | 0.69% |
| Jul 9, 2026 | 3.87B | -1.52% |
| Jul 8, 2026 | 3.93B | 1.58% |
| Jul 7, 2026 | 3.86B | 3.94% |
| Jul 6, 2026 | 3.72B | -1.28% |
| Jul 2, 2026 | 3.77B | 6.56% |
| Jul 1, 2026 | 3.53B | 1.42% |
| Jun 30, 2026 | 3.49B | -6.24% |
| Jun 29, 2026 | 3.72B | 1.35% |
| Jun 26, 2026 | 3.67B | 9.26% |
| Jun 25, 2026 | 3.36B | -3.51% |
| Jun 24, 2026 | 3.48B | -0.69% |
| Jun 23, 2026 | 3.50B | -0.11% |
| Jun 22, 2026 | 3.51B | 6.54% |
| Jun 18, 2026 | 3.29B | -0.69% |
| Jun 17, 2026 | 3.31B | -2.11% |
| Jun 16, 2026 | 3.39B | 6.32% |
| Jun 15, 2026 | 3.18B | -8.25% |
| Jun 12, 2026 | 3.47B | -3.07% |
| Jun 11, 2026 | 3.58B | 50.78% |
| Jun 10, 2026 | 2.38B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| CRISPR Therapeutics AG | 4.60B |
| Edgewise Therapeutics | 4.48B |
| Caris Life Sciences | 4.42B |
| ACADIA Pharmaceuticals | 4.35B |
| Relay Therapeutics | 4.06B |
| Viking Therapeutics | 4.05B |
| Celcuity | 4.01B |
| Tango Therapeutics | 3.86B |